摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-N-(5-Amino-pyridin-3-yl)-N''-cyano-N'-(1-phenylpropyl)guanidine | 170793-45-0

中文名称
——
中文别名
——
英文名称
(R)-N-(5-Amino-pyridin-3-yl)-N''-cyano-N'-(1-phenylpropyl)guanidine
英文别名
(R)-N-(5-Amino-3-pyridyl)-N"-cyano-N'-(1-phenylpropyl)guanidine;1-(5-aminopyridin-3-yl)-3-cyano-2-[(1R)-1-phenylpropyl]guanidine
(R)-N-(5-Amino-pyridin-3-yl)-N''-cyano-N'-(1-phenylpropyl)guanidine化学式
CAS
170793-45-0
化学式
C16H18N6
mdl
——
分子量
294.359
InChiKey
TWSVUGSHXMWEQD-OAHLLOKOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    22
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    99.1
  • 氢给体数:
    3
  • 氢受体数:
    4

文献信息

  • CYANOGUANIDINES AS K-CHANNEL BLOCKERS
    申请人:PHARMACIA & UPJOHN COMPANY
    公开号:EP0741708A1
    公开(公告)日:1996-11-13
  • US5668157A
    申请人:——
    公开号:US5668157A
    公开(公告)日:1997-09-16
  • [EN] CYANOGUANIDINES AS K-CHANNEL BLOCKERS<br/>[FR] CYANOGUANIDINES UTILISEES COMME AGENTS BLOQUANTS DES CANAUX K
    申请人:PHARMACIA & UPJOHN COMPANY
    公开号:WO1995020579A1
    公开(公告)日:1995-08-03
    (EN) Cyanoguanidine compounds of Formula (I) and their pharmaceutically acceptable acid addition salts where R1 is hydrogen or methyl; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl C3-C5 cycloalkyl, C3-C5 cycloalkenyl, hydroxymethyl, methoxy C1-C5 alkyl, or R1 and R2 are combined to form a C3-C6 carboxyclic ring; R3 and R4 are each independently selected to be hydrogen, C1-C4 alkyl, F, Cl, Br, I or CF3; R5 is hydrogen, F or Cl; R6 is hydrogen, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)mOC1-C3 alkyl, NHC(O)C1-C3 alkyl, F, Cl, Br, C1-C3 alkyl, NH(CH2)mF, 1-imidazolyl, NHOC1-C3 alkyl, NHOH, NHSO2C1-C3 alkyl, SH, SC1-C3 alkyl, NHC(O)OC1-C3 alkyl, NHC(O)NHC1-C3 alkyl, NHSO2NHC1-C3 alkyl, NHSO2N(C1-C3 alkyl)2 or amino acid amide; R7 is C1-C7 alkyl, NH2, NHC1-C3 alkyl, N(C1-C3 alkyl)2, CF3, F, Cl, Br, I, OC1-C3 alkyl, OH, COOH, C(O)OC1-C3 alkyl, C(O)NH2, C(O)NHC1-C3 alkyl, C(O)C1-C3 alkyl, C(O)N(C1-C3 alkyl)2, SO2NH2, SO2NHC1-C3 alkyl, CN, SO2N(C1-C3 alkyl)2, NHC(O)C1-C3 alkyl, NHC(O)NHC1-C3 alkyl, NHC(O)N(C1-C3 alkyl)2, NHSO2NHC1-C3 alkyl, NHSO2N(C1-C3 alkyl)2, SH, SC1-C3 alkyl, NO2, SO2C1-C3 alkyl, NHC(O)OC1-C3 alkyl, amino acid amide or hydrogen; R8 is hydrogen, C1-C6 alkyl, NH2, NHC1-C3 alkyl, N(CH3)2, N(C2H5)2, F, Cl, Br, OC1-C3 alkyl or OH; and where m is 2 or 3 and n is 0 or 1 (except for those compounds where R8 is hydrogen and R6 is hydrogen, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)m-OC1-C3 alkyl, NHC(O)C1-C3 alkyl, Cl or Br). The compounds of Formula (I) are potassium channel blockers useful in the treatment of cardiovascular disorders such as congestive heart failure and hypertension and as a diuretic.(FR) L'invention se rapporte à des composés de cyanoguanidine de la formule (I) et à leurs sels d'addition acides pharmaceutiquement acceptables, formule dans laquelle R1 représente hydrogène or méthyle; R2 représente alkyle C1-C6, alcényle C2-C6, alkynyle C2-C6, cycloalkyle C3-C5, cycloalcényle C3-C5, hydroxyméthyle, méthoxy C1-C5 alkyle, ou bien R1 et R2 sont combinés pour former un cycle carbocyclique C3-C6; R3 et R4 sont chacun, indépendamment, sélectionnés parmi hydrogène, alkyle C1-C4, F, Cl, Br, I ou CF3; R5 représente hydrogène, F ou Cl; R6 représente hydrogène, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)mOC1-C3 alkyle, NHC(O)C1-C3 alkyle, F, Cl, Br, alkyle C1-C3 , NH(CH2)mF, 1-imidazolyle, NHOC1-C3 alkyle, NHOH, NHSO2C1-C3 alkyle, SH, SC1-C3 alkyle, NHC(O)OC1-C3 alkyle, NHC(O)NHC1-C3 alkyle, NHSO2NHC1-C3 alkyle, NHSO2N(alkyle C1-C3)2 ou un amide d'acide aminé; R7 représente alkyle C1-C7, NH2, NHC1-C3 alkyle, N(alkyle C1-C3)2, CF3, F, Cl, Br, I, OC1-C3 alkyle, OH, COOH, C(O)OC1-C3 alkyle, C(O)NH2, C(O)NHC1-C3 alkyle, C(O)C1-C3 alkyle, C(O)N(alkyle C1-C3)2, SO2NH2, SO2NHC1-C3 alkyle, CN, SO2N(alkyle C1-C3)2, NHC(O)C1-C3 alkyle, NHC(O)NHC1-C3 alkyle, NHC(O)N(alkyle C1-C3)2, NHSO2NHC1-C3 alkyle, NHSO2N(alkyle C1-C3)2, SH, SC1-C3 alkyle, NO2, SO2C1-C3 alkyle, NHC(O)OC1-C3 alkyle, un amide d'acide aminé ou hydrogène; R8 représente hydrogène, alkyle C1-C6, NH2, NHC1-C3 alkyle, N(CH3)2, N(C2H5)2, F, Cl, Br, OC1-C3 alkyle ou OH; et où m vaut 2 ou 3 et n vaut 0 ou 1 (excepté pour les composés où R8 représente hydrogène et R6 représente hydrogène, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)m-OC1-C3 alkyle, NHC(O)C1-C3 alkyle, Cl ou Br). Les composés de la formule (I) sont des agents bloquants des canaux de potassium utiles dans le traitement de troubles cardiovasculaires, tels que l'insuffisance cardiaque congestive et l'hypertension, et agissent également comme diurétiques.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫